Amid growing demand for ALS treatments, a preliminary analysis finds an experimental medicine that may be approved later this year by U.S. regulators would not be cost effective if it carries the same high price as an older medication.
The analysis examined Radicava, an intravenous medicine that was approved five years ago and will soon be available as a tablet, with a medication that is currently under review by the Food and Drug Administration. Developed by Amylyx Pharmaceuticals, the newer drug is also a tablet and has sparked optimism among ALS patient groups that are clamoring for useful treatments.
Continue to STAT+ to read the full story…
Click this link for the original source of this article.
Author: Ed Silverman
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
